Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCA-19: Cellular Immuno-Therapy for COVID-19 ARDS
NCT04400032Phase 2Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of human umbilical cord mesenchymal stem cells in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (3 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 at 1 year. Started May 2020; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04400032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04400032.